LDL cholesterol-lowering and circulating PCSK9 levels: comparison with doubling dose of atorvastatin and ezetimibe combination following standard-dose atorvastatin non-response

Trial Profile

LDL cholesterol-lowering and circulating PCSK9 levels: comparison with doubling dose of atorvastatin and ezetimibe combination following standard-dose atorvastatin non-response

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2012

At a glance

  • Drugs Atorvastatin (Primary) ; Ezetimibe
  • Indications Hypercholesterolaemia
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 06 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top